FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306293824> ?p ?o ?g. }

• W4306293824 endingPage "1379" @default.
• W4306293824 startingPage "1370" @default.
• W4306293824 abstract "Abstract Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We report health-related quality of life (HRQoL) outcomes in patients with ulcerative colitis in the phase 3 open-label, long-term extension study, OCTAVE Open. Methods The Inflammatory Bowel Disease Questionnaire (IBDQ), EuroQoL-5 Dimensions Health Questionnaire, and 36-Item Short Form Survey scores were analyzed up to month (M) 72 in 4 subpopulations: patients in remission at baseline (maintenance remitters) assigned tofacitinib 5 mg twice daily and patients not in remission at baseline (maintenance nonremitters, maintenance treatment failures, and induction nonresponders [IndNRs]) assigned tofacitinib 10 mg twice daily in OCTAVE Open. Data were analyzed overall and stratified by corticosteroid use at baseline, prior tumor necrosis factor inhibitor failure, and prior immunosuppressant failure. Results Among maintenance remitters and nonremitters, HRQoL outcomes were maintained up to M72: 80.0% and 100.0% of patients had an IBDQ total score ≥170, respectively. At baseline, 7.4% of maintenance treatment failures had an IBDQ total score ≥170, and this increased to 54.3% and 75.0% at M2 and M72, respectively. Corresponding values for IndNRs were 22.6%, 51.0%, and 86.0%. HRQoL outcomes were independent of treatment history. Among patients not in remission at baseline, improvement in EuroQoL-5 Dimensions Health Questionnaire and 36-Item Short Form Survey scores was maintained or achieved by M2, and steady to M72 or M33, with maintenance treatment failures and IndNR subpopulations undergoing the biggest improvements from baseline. Conclusions A continued favorable impact on HRQoL was revealed with long-term tofacitinib treatment in OCTAVE Open, regardless of baseline remission status or treatment history. (ClinicalTrials.gov; number: NCT01470612)." @default.
• W4306293824 created "2022-10-15" @default.
• W4306293824 creator A5012501013 @default.
• W4306293824 creator A5019801327 @default.
• W4306293824 creator A5019850545 @default.
• W4306293824 creator A5027087096 @default.
• W4306293824 creator A5034073531 @default.
• W4306293824 creator A5040354010 @default.
• W4306293824 creator A5047749668 @default.
• W4306293824 creator A5049169459 @default.
• W4306293824 creator A5081674539 @default.
• W4306293824 date "2022-10-15" @default.
• W4306293824 modified "2023-10-08" @default.
• W4306293824 title "Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open" @default.
• W4306293824 cites W1671682816 @default.
• W4306293824 cites W1823008566 @default.
• W4306293824 cites W1974696491 @default.
• W4306293824 cites W2037377025 @default.
• W4306293824 cites W2093375795 @default.
• W4306293824 cites W2132566639 @default.
• W4306293824 cites W2171122944 @default.
• W4306293824 cites W2323558841 @default.
• W4306293824 cites W2534412234 @default.
• W4306293824 cites W2611548364 @default.
• W4306293824 cites W2759956418 @default.
• W4306293824 cites W2774339715 @default.
• W4306293824 cites W2982410008 @default.
• W4306293824 cites W3049061167 @default.
• W4306293824 cites W3082374255 @default.
• W4306293824 cites W3091780354 @default.
• W4306293824 cites W3097678427 @default.
• W4306293824 cites W3112731988 @default.
• W4306293824 cites W3115410759 @default.
• W4306293824 cites W3127381949 @default.
• W4306293824 cites W3216828262 @default.
• W4306293824 cites W4206974011 @default.
• W4306293824 cites W4211138554 @default.
• W4306293824 cites W4231456852 @default.
• W4306293824 cites W4292806894 @default.
• W4306293824 doi "https://doi.org/10.1093/ibd/izac222" @default.
• W4306293824 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36242764" @default.
• W4306293824 hasPublicationYear "2022" @default.
• W4306293824 type Work @default.
• W4306293824 citedByCount "0" @default.
• W4306293824 crossrefType "journal-article" @default.
• W4306293824 hasAuthorship W4306293824A5012501013 @default.
• W4306293824 hasAuthorship W4306293824A5019801327 @default.
• W4306293824 hasAuthorship W4306293824A5019850545 @default.
• W4306293824 hasAuthorship W4306293824A5027087096 @default.
• W4306293824 hasAuthorship W4306293824A5034073531 @default.
• W4306293824 hasAuthorship W4306293824A5040354010 @default.
• W4306293824 hasAuthorship W4306293824A5047749668 @default.
• W4306293824 hasAuthorship W4306293824A5049169459 @default.
• W4306293824 hasAuthorship W4306293824A5081674539 @default.
• W4306293824 hasBestOaLocation W43062938241 @default.
• W4306293824 hasConcept C126322002 @default.
• W4306293824 hasConcept C159110408 @default.
• W4306293824 hasConcept C1862650 @default.
• W4306293824 hasConcept C197934379 @default.
• W4306293824 hasConcept C2776233030 @default.
• W4306293824 hasConcept C2776694085 @default.
• W4306293824 hasConcept C2777575956 @default.
• W4306293824 hasConcept C2778260677 @default.
• W4306293824 hasConcept C2778283404 @default.
• W4306293824 hasConcept C2778886723 @default.
• W4306293824 hasConcept C2779134260 @default.
• W4306293824 hasConcept C2779951463 @default.
• W4306293824 hasConcept C2780479503 @default.
• W4306293824 hasConcept C3019800554 @default.
• W4306293824 hasConcept C71924100 @default.
• W4306293824 hasConceptScore W4306293824C126322002 @default.
• W4306293824 hasConceptScore W4306293824C159110408 @default.
• W4306293824 hasConceptScore W4306293824C1862650 @default.
• W4306293824 hasConceptScore W4306293824C197934379 @default.
• W4306293824 hasConceptScore W4306293824C2776233030 @default.
• W4306293824 hasConceptScore W4306293824C2776694085 @default.
• W4306293824 hasConceptScore W4306293824C2777575956 @default.
• W4306293824 hasConceptScore W4306293824C2778260677 @default.
• W4306293824 hasConceptScore W4306293824C2778283404 @default.
• W4306293824 hasConceptScore W4306293824C2778886723 @default.
• W4306293824 hasConceptScore W4306293824C2779134260 @default.
• W4306293824 hasConceptScore W4306293824C2779951463 @default.
• W4306293824 hasConceptScore W4306293824C2780479503 @default.
• W4306293824 hasConceptScore W4306293824C3019800554 @default.
• W4306293824 hasConceptScore W4306293824C71924100 @default.
• W4306293824 hasFunder F4320307765 @default.
• W4306293824 hasIssue "9" @default.
• W4306293824 hasLocation W43062938241 @default.
• W4306293824 hasLocation W43062938242 @default.
• W4306293824 hasLocation W43062938243 @default.
• W4306293824 hasLocation W43062938244 @default.
• W4306293824 hasOpenAccess W4306293824 @default.
• W4306293824 hasPrimaryLocation W43062938241 @default.
• W4306293824 hasRelatedWork W2611548364 @default.
• W4306293824 hasRelatedWork W2937462161 @default.
• W4306293824 hasRelatedWork W2944375061 @default.
• W4306293824 hasRelatedWork W2998896570 @default.
• W4306293824 hasRelatedWork W3000720042 @default.

• next